Compare Compass Inc. Class A Common Stock (COMP) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Compass Inc. Class A Common Stock vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Compass Inc. Class A Common Stock trades at $9.35 (market cap $7.31B), while Halozyme Therapeutics Inc. Common Stock trades at $110.64 (market cap $12.58B). The key difference: Halozyme Therapeutics Inc. Common Stock is the larger of the two by market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Compass Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Compass Inc. Class A Common Stock for 0 Days and Halozyme Therapeutics Inc. Common Stock for 0 Days on average.
| COMP | HALO | |
|---|---|---|
Market Cap | $7.31B | $12.58B |
Volume | 15,861,865 | 2,179,278 |
Sector | Real Estate | Health |
52-Week High | $13.58 | $115.22 |
52-Week Low | $6.68 | $61.63 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $10.72B | $14.49B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Compass Inc. Class A Common Stock
Compass is a technology-enabled residential real estate company. Its platform provides agents with tools for customer relationships, marketing, client service, and transactions, alongside brokerage, title, escrow, and mortgage services.
Read more on COMP →About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →
